Chera Simona, Herrera Pedro L
Department of Clinical Science, Faculty of Medicine and Dentistry, University of Bergen, Jonas Lies vei 65, 5021 Bergen, Norway.
Department of Genetic Medicine & Development, Faculty of Medicine, Institute of Genetics and Genomics in Geneva (iGE3), and Centre facultaire du diabète, University of Geneva, 1 rue Michel-Servet, 1211 Geneva-4, Switzerland.
Curr Opin Genet Dev. 2016 Oct;40:1-10. doi: 10.1016/j.gde.2016.05.010. Epub 2016 Jun 3.
The impaired ability to produce or respond to insulin, a hormone synthetized by the pancreatic β-cells, leads to diabetes. There is an excruciating need of finding new approaches to protect or restore these cells once they are lost. Replacement and ex vivo directed reprogramming methods have an undeniable therapeutic potential, yet they exhibit crucial flaws. The in vivo conversion of adult cells to functional insulin-producing cells is a promising alternative for regenerative treatments in diabetes. The stunning natural transdifferentiation potential of the adult endocrine pancreas was recently uncovered. Modulating molecular targets involved in β-cell fate maintenance or in general differentiation mechanisms can further potentiate this intrinsic cell plasticity, which leads to insulin production reconstitution.
胰腺β细胞合成的激素胰岛素产生或响应能力受损会导致糖尿病。一旦这些细胞丢失,迫切需要找到新的方法来保护或恢复它们。替代和体外定向重编程方法具有不可否认的治疗潜力,但它们存在关键缺陷。将成体细胞体内转化为功能性胰岛素产生细胞是糖尿病再生治疗的一种有前景的替代方法。最近发现了成体内分泌胰腺惊人的自然转分化潜力。调节参与β细胞命运维持或一般分化机制的分子靶点可以进一步增强这种内在的细胞可塑性,从而导致胰岛素产生的重建。